Follow on Google News News By Tag Industry News News By Location Country(s) Industry News
Follow on Google News | Kindred Bio Announces Protocol Concurrences from the FDA on Pivotal StudiesFDA issues the equivalent of a Special Protocol Assessment on the design of KIND-001 and KIND-002 Pivotal Studies
Richard Chin, CEO of Kindred Bio, stated, “We are delighted to receive concurrence from the FDA on our first two pivotal studies. The concurrences are major advances toward our goal to bringing the benefits of KIND-001 and KIND-002 to our patients.” About Kindred Bio “Best Medicines for Our Best Friends” www.kindredbio.com Kindred Bio is a leading veterinary biotechnology company, focused on developing breakthrough therapies for dogs, cats, and horses. Founded by industry veterans formerly from Genentech and Elan Pharmaceuticals who have experience developing antibody drugs such as Lucentis®, Tysabri®, Xolair®, and Rituxan®, Kindred Bio is committed to bringing the very best science and medicine to companion animals. About KIND-001 KIND-001 is a cytokine inhibitor being developed for inflammatory conditions in dogs. About KIND-002 KIND-002 is molecule being developed for a dermatological disease in dogs. Forward-Looking Statements Forward-looking statements in this news release involve inherent risks and uncertainties and a number of important factors could cause actual results to differ materially from those contained in such forward-looking statements. These factors include, but are not limited to uncertainties associated with: drug development and regulatory review process, scientific discovery process, competition, pricing environment, financing, intellectual property, and evolution of the companion animal market. The company undertakes no obligation to publicly release the result of any revisions to these forward-looking statements that may be made to reflect events or circumstances after the date. Trademark Acknowledgements Lucentis® is a registered trademarks of Genentech, Inc. Rituxan® is a registered trademark of Biogen Idec Inc. Xolair® is a registered trademark of Novartis AG Corporation. Tysabri® is a trademark of Elan Pharmaceuticals, Inc. Contact Denise Bevers Kindred Bio denise.bevers@ (650) 701-7908 End
Account Email Address Account Phone Number Disclaimer Report Abuse
|
|